
This Bengaluru-based firm is quietly saving thousands of mothers and newborns—here's how
For Arun Agarwal, who was born in Alwar, the reports of stillborn babies and maternal deaths were familiar occurrences. For years, he has heard these heartbreaking stories. However, his perspective changed when he learnt more about the high maternal and infant mortality rates in developing countries during his time at Vellore Institute of Technology, prompting him to seek a solution.
According to the Rural Health Statistics report for 2022-23, there is a severe shortage of gynaecologists in rural India. The report highlights that against a requirement of 5,491, there are only 1,442 gynaecologists available, resulting in a shortfall of 74.2%.
After graduation, Agarwal pursued a biomedical engineering course and visited several hospitals and labour wards across the country for his research.
In 2015, Agarwal joined the Biotechnology Industry Research Assistance Council (BIRAC), which was looking for entrepreneurs working in maternity and child healthcare. A year later, the idea for Janitri Innovations germinated. Janitri is focused on providing affordable and accessible maternal and neonatal healthcare. Today, it has a wide range of products for both hospitals and at-home services for mothers.
Its flagship product, Keyar, which initially started as an affordable and portable foetal monitoring device, today has different variants, such as a beltless ECG/EMG-based foetal maternal labour monitoring patch, postpartum haemorrhage risk detection, a wireless & portable smart CTG machine, a smart newborn jaundice monitor, a handheld foetal monitor and a home NST (Non-Stress Test) for high-risk mothers. Janitri has been granted seven patents; it has also filed 19 patents. The company has monitored over 200,000 mothers, catered to more than 800 hospitals and saved 8,000 lives operating in more than 11 countries.
Live Events
Janitri Innovations was also the winner of India's Top MSME of the Year- Micro, at the ET MSME Awards 2024.
Janitri Innovations was also the winner of India's Top MSME of the Year- Micro, at the ET MSME Awards 2024.
Maternity miracle
Like many innovative start-ups, Janitri had its own share of a long gestation period. It started pilots in 2016 and launched the product commercially in 2021 after getting regulatory approvals.
'It's been four years since the commercialisation of our products. We have added so many other products and use cases, including post-delivery and newborn monitoring, since then. We were a team of 15 people in 2019 when we had to go through the ISO regulatory approvals. Now, we have grown into a team of 70 people,' Agarwal says.
Janitri's other flagship product, Keyar Echo, is a first-of-its-kind home pregnancy monitoring device that allows expectant mothers to monitor their baby's heartbeat and well-being from home, ensuring timely medical decisions. Keyar's other variants, Keyar DT Max and Keyar DT Max Plus, enable advanced and smart pregnancy monitoring and immediate postpartum monitoring for timely intervention. It allows remote monitoring with data access on mobile apps for the doctors so timely action can be taken. Janitri has also enhanced hospital efficiency through Navam software, which digitises labour monitoring with AI-driven alerts and partograph generation, ensuring better clinical outcomes. These innovations are backed by patented technologies, extensive clinical validation and a user-centric approach addressing gaps in both hospital-based and home-based care.
Janitri's Daksh SI Max is a smart obstetric shock index monitor, which is a portable medical-grade wireless device that helps doctors predict postpartum haemorrhage risk.
Bengaluru-based Latha Venkatram, a senior obstetrician- gynaecologist, who has been with Janitri since its inception, explained that back then they had been looking for a low-cost, effective foetal monitoring device using electrical impulses, and this is where Janitri's innovation came to the rescue. 'There was only one other such product, which was expensive, but Janitri was a made-in-India device, affordable and fantastic. The partographs produced are better with this; we have compared it with a traditional Huntley Partograph monitor, and the graph is satisfactory. The other important feature is the maternal heart rate is also recorded. So twin monitors are also available now, so the foetal surveillance is quite effective, easy and fairly cost-effective,' she says.
The company was also a part of Shark Tank India Season 2 in 2023. Agarwal went with Namita Thapar, Executive Director of Emcure Pharmaceuticals, for an offer of Rs 1 crore for 2.5% equity.
Talking about Janitri's success overseas, Agarwal explains that they see similar maternal healthcare issues in the Global South.
'The field of pregnancy and newborn care faces issues in other developing countries like Southeast Asia, Africa, and South America. So, we get a lot of queries from those countries from doctors, hospital distributors and other stakeholders. We have deployed the product in Kenya, South Africa, Malaysia, Brazil, among other countries,' he says, adding that now the company is not very aggressive for the international market and will become so after getting international approvals from the FDA and CE.
Agarwal highlighted that different variants of their products make it affordable to all—starting from Rs 40,000 to over Rs 2 lakh for a premium version. In hospitals, the devices start at Rs 1 lakh each.
What next? The company is now focusing on building products and features for the entire journey of pregnancy, labour and newborns up to 2 years old. 'Our whole focus is purely from the perspective of some kind of vital monitoring and AI-based early-decision-making algorithms which can give support or early alerts to the healthcare worker or mother at home,' he says.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hans India
an hour ago
- Hans India
India's forex reserves drop $1.24 bln to $691.49 bln
Mumbai: India's forex reserves dropped by $1.237 billion to $691.485 billion for the week ended May 30, the RBI said on overall reserves had jumped by $6.992 billion to $692.721 billion in the previous reporting week. The forex reserves had touched an all-time high of $704.885 billion in end-September 2024. Earlier in the day, RBI Governor Sanjay Malhotra said that at $691.5 billion, the reserves are sufficient to fund more than 11 months of goods imports and about 96 per cent of external debt outstanding. For the week ended May 30, foreign currency assets, a major component of the reserves, decreased by $1.952 million to $584.215 billion, the data released on Friday showed. Expressed in dollar terms, the foreign currency assets include the effect of appreciation or depreciation of non-US units like the euro, pound and yen held in the foreign exchange reserves. The gold reserves increased by $723 million to $84.305 billion during the week, the RBI said.


Economic Times
8 hours ago
- Economic Times
De Beers draws interest from billionaire Agarwal, Qatari funds, sources say
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Diamond giant De Beers has drawn interest from at least six consortia, including billionaire Anil Agarwal , Indian diamond firms and Qatari investment funds, sources close to the companies told Beers is being carved out of Anglo American as the London-listed miner refocuses on copper and iron ore but the move comes with global diamond prices under chairman of Vedanta Resources , which has mines in Zambia and South Africa, is among the interested parties, as part of a bigger group, two sources and Agarwal both declined to companies including KGK Group and Kapu Gems, which dominate the domestic cutting and polishing trade, and are De Beers's biggest customers, have also expressed an interest, two sources with knowledge of the matter Group and Kapu Gems did not respond to requests for American, whose book value for De Beers stands at $4.9 billion, following $3.5 billion in impairments over the last two years, said it has retained financial advisers Morgan Stanley, Goldman Sachs and Centerview to help with a sale or a demerger and potential listing.


The Hindu
8 hours ago
- The Hindu
Haryana IMA seeks clarity on State govt.'s cashless treatment scheme for accident victims
In the wake of the Haryana Health Department's order to onboard all hospitals for a cashless road accident victims treatment scheme, the State chapter of the Indian Medical Association (IMA) has sought clarity on its various aspects, including the rates prescribed for the treatment. The scheme, launched in Haryana earlier this year as a pilot project along with five other States, had failed to take off after the private hospitals backed out of it citing several reasons, including the meagre treatment rates. In a letter to the Director General Health Services (DGHS) seeking clarification on the various aspects of the scheme, the Haryana IMA has sought details about the rates prescribed for the services such as consultation, ICU charges, room rent; the mode of payment; procedure for the empanelment of non-Ayushman Hospitals and access to the portal for the registration of these cases. The DGHS has directed all civil surgeons to onboard all hospitals for the scheme, especially those not empanelled under the Ayushman Bharat. Under the scheme, notified by Ministry of Road Transport and Highways in 2025, the road accident victims would be administered cashless emergency care of up to ₹1.5 lakh with a cap of maximum of seven days. The scheme is applicable across all categories of roads including National and State Highways and municipal roads. Former IMA chief Ajay Mahajan told The Hindu over phone that the government had earlier offered very low rates, only ₹1,000 per day including ICU charges, surgery, medicines and the investigations expenses. 'It is a good scheme and could help save road accident victims offering timely treatment. But the rates offered earlier were not practical. Many Ayushaman empanelled hospitals came forward, but had to back out due to very low rates and delayed payments. The road accident victims suffer multiple injuries and might require a lot of investigations such as frequent MRI. So, this scheme failed to take off in Haryana and now DGHS has asked civil surgeons to enrol other hospitals too. But there is no clarity on how the hospitals would be paid. This is bound to fail again,' said Dr. Mahajan. 'Meagre payment' In March too, the IMA had written to the DGHS after the launch of the scheme expressing concerns over low rates and lack of clarity on various issues. 'Unfortunately, at present the pilot project is being launched in Haryana without proper preparations. There are no proper guidelines on how the payments will be made, no separate MoU has been done and few cases that have been claimed are being paid a measly sum of ₹1,000 per day for general ward for a head injury case in Intensive Care Unit,' the letter had read. DGHS Manish Bansal did not respond to calls and text messages to seek his response.